bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract LB-54: Gap Junction Enhancer Increases Efficacy of Cisplatin to Attenuate Mammary Tumor Growth
Authors: Shishido Stephanie N. , Nguyen Thu A. 
Published: July 2012

Abstract
INTRODUCTION: Cisplatin treatment has an overall 19% response rate in animal models with malignant tumors (Knapp et al. 1988). Increasing gap junction activity or enhancing GJIC in tumor cells provides the targets to enhance antineoplastic therapies. A new class of substituted quinolines (PQs) possesses inhibitory activities against breast cancer cells through the enhancement of gap junctional intercellular communication. We examined the effect of combinational treatment of PQ and antineoplastic drugs in an animal model to show an increase in efficacy of antineoplastic drugs via the enhancement of gap junctions.
MATERIALS AND METHODS: Mice were implanted with estradiol-17ß (1.7 mg/pellet) before the injection of 1 × 107 T47D breast cancer cells subcutaneously into the inguinal region of mammary fat pad. Animals were treated intraperitoneally with DMSO (control), Cisplatin (3.5mg/kg), PQ (25mg/kg), or a combining treatment of Cisplatin and PQ.
RESULTS: Cisplatin alone decreased mammary tumor growth by 29% while combinational treatment of Cisplatin and PQ showed a 36% reduction after 7 treatments at every 2 days. Histological results showed a significant increase of gap junction proteins, Cx43 and Cx26, in PQ-treated tissues compared to control or Cisplatin. Furthermore, evidence of highly stained caspase 3 in tumors of combinational treatment (PQ and Cisplatin) was seen compared to Cisplatin alone.
CONCLUSIONS: We have showed for the first time an increase in the efficacy of antineoplastic drugs via the enhancement of gap junctions with PQs, a specific class of gap junction enhancers.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-54. doi:10.1158/1538-7445.AM2011-LB-54
Abstract LB-56: LGR5 is differentially expressed in hepato-gastrointestinal tumors
Authors: Simon Eva , Petke Diana , Böger Christine , Warneke Viktoria , Behrens Michael , Rocken Christoph 
Published: July 2012

Abstract
Background: The orphan G-protein-coupled receptor (GPCR) and Wnt-target protein LGR5 was recently identified as a stem cell marker for cells with intestinal differentiation. In this study we generated a polyclonal anti-LGR5 antibody to investigate protein expression in various hepato-gastrointestinal carcinomas and its correlation with clinico-pathological patient characteristics.
Materials and Methods: Differential expression of LGR5 was studied on transcriptional (real time-polymerase chain reaction) and translational level (immunohistochemistry) in carcinomas and corresponding normal mucosal specimens comprising seven different primary tumor sites, i.e. oesophagus, pancreas, stomach, liver, colon and rectum. The putative clinico-pathological relevance of LGR5-expression in terms of patient survival was studied in tissue micro arrays obtained from a cohort of 488 gastric carcinomas.
Results: We succeeded to establish and characterize a highly specific antibody that recognizes the C-terminal tail of LGR5. LGR5 was differentially expressed on transcriptional and translational level in adenocarcinomas of the oesophagus, pancreas, stomach, colon, rectum, hepatocellular and cholangiocellular carcinoma of the liver compared with the adjacent non-neoplastic tissue. However, in gastric cancer tissue microarrays the expression of LGR5 had no impact on patient survival. Nevertheless, expression of LGR5 by endothelial cells of tumor vessels correlated significantly with the tumor type and tumor grade.
Conclusion: Our results substantiate the significance of LGR5 on the biology of hepato-gastrointestinal carcinomas and provide evidence for its function as potential stem cell marker and candidate therapeutic target in the stomach. With our anti-LGR5 antibody we now have a useful tool for detection and further analyzes of LGR5 biological function.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-56. doi:10.1158/1538-7445.AM2011-LB-56
Abstract LB-57: Multiplexed detection of phospho-ERK as a marker of H-Ras signaling, EGFR and cancer stem cell marker expression in breast cancer cells recovered from human blood
Authors: Navaraj Arunasalam , Dicker David T. , Dolloff Nathan , El-Deiry Wafik S. 
Published: July 2012

Abstract
Breast cancer is the most frequent malignancy among women, causing 373,000 deaths per year worldwide. Recent studies indicate that breast cancer is initiated by breast cancer stem cells (BCSCs) which express CD44+/high CD24−/low surface markers. Mammospheres are non-adherent spherical cell clusters grown in selective culture conditions. Our experimental results using mammosphere cultures of different metastatic, human breast cancer cells such as MDA-MB-231 and MDA-MB-468, showed drastic enrichment of breast cancer stem-like cells with the phenotype of CD44+/high CD24−/low in flow cytometry analysis, with specific antibody conjugates. Using the FDA-approved Veridex CellSearch System, we successfully recovered Epcam+/cytokeratin+/CD45− breast cancer cells from 7.5 ml of human blood to which a known number of MDA-MB-468 or H-Ras transformed MCF10A cells had been added. When these recovered breast cancer cells were subjected to Q-Dot conjugated p-ERK antibody staining and quantification, signal intensity clearly demonstrated higher levels of nuclear p-ERK in MCF10A-Ras cells whereas immunostaining for surface EGFR expression was much stronger in MDA-MB-468 cells. We are modeling mammosphere-derived breast cancer cells enriched for stem cell markers by orthotopic implantation into mammary fat pads of nude mice, sampling blood from tumor-bearing animals to detect the presence of Circulating Tumor Cells (CTCs) using the Veridex CellSearch System and further for breast cancer specific multiplexed marker analysis. These stem cell marker enriched xenografted human breast tumors are facilitating our understanding of cellular signaling pathways active in CTCs, and also in understanding of the role of cancer stem cells in human breast cancer metastasis.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-57. doi:10.1158/1538-7445.AM2011-LB-57
Abstract LB-60: A Local Consumer Research Panel's Role in the work of the National Institute for Health Research (NIHR) in the U.K
Authors: Ardron David 
Published: July 2012

Abstract
The poster explains how patient advocacy fits into the world of health research, the relationship between research networks, and how research is planned at both the national and local levels in the United Kingdom. It describes the role of a local consumer research panel in helping to enhance research for maximum patient benefit. David Ardon has been a member and chair of a local panel for eight years and of the national consumer research group for seven years. The poster explains where in the research cycle patients and caregivers have been active, demonstrating the logos of local and national research organizations, and in diagrammatic form, showing the kind of activities that a consumer researcher tackles.
The North Trent Cancer Research Network Consumer Research Panel was established in 2001 by the Academic Unit of Supportive Care at the University of Sheffield. North Trent is an area in the North East Midlands of England. The panel works alongside and is a constituent of the National Cancer Research Institute Consumer Liaison Group. The panel, composed of 40 past and current cancer patients and caregivers, is funded by the North Trent Cancer Network and the South Yorkshire CLRN to provide a consumer perspective at strategic meetings within North Trent and for individual research studies within the network. The panel has hosted and led ten conferences aimed at raising awareness of clinical research. The objective of the panel is to improve the quality of communication and information exchange between health care professionals, patients, and caregivers by providing a consumer perspective at all stages of cancer research and clinical trials. The governing body of health research in the U.K. is the National Institute for Health Research, which monitors eight research areas, one of which is cancer. Cancer research is governed and managed by the National Cancer Research Institute (NCRI), and the National Cancer Research Network (NCRN). Health research locally is delivered by a Comprehensive Local Research Network (CLRN). Mr. Ardon's local CLRN is the South Yorkshire CLRN, and this group includes the North Trent Cancer Research Network.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-60. doi:10.1158/1538-7445.AM2011-LB-60
Abstract LB-62: Breast Cancer Research Advocacy
Authors: Blath Lorry , Blath Lorry 
Published: July 2012

Abstract
Lorry Blath works with fellow research advocates who are breast cancer survivors with a passion for learning the science of breast cancer and applying it to a variety of local and national opportunities. Advocates support research by understanding and conveying the patient's point of view to the medical and research community. The St. Louis Research Advocacy Committee is the only such group associated with a Susan G. Komen Affiliate in the country.
At the advocacy monthly meetings members review articles, mentor each other, introduce activities that match their advocacy interests and talents, and invite speakers several times a year to the “Ask the Expert” series. In the last two years the speakers have included: Dr. Graham Colditz, Dr. Ron Bose, Dr. Shiela Stewart, Dr. Will Gillanders, Dr. Craig Allred, and representatives from the Breast Navigation Program.
The committee organizes a workshop to introduce advocacy to potential candidates. This seminar presents volunteer and educational opportunities, basic breast cancer science, and encourages the attendees to set personal goals. Two breast cancer researchers give lectures in their particular area of interest, followed by demonstrations in their labs. After the workshop, the attendees choose their level of involvement: they may serve in official capacities as community representatives on hospital IRBs, DoD grant reviewers, Komen national and community grant reviewers, and asked to collaborate with scientists on their grant submissions. A few aspire to more advanced instruction by representing Susan G. Komen at national research and/or educational conferences and sharing their gained knowledge with the group. In April, 2011, the research advocacy committee will hold its first RA201 workshop. This seminar, to be held at the Washington University Genome Center, will host breast cancer scientists explaining their original research.
The committee's first community-wide event will take place in March at the Missouri History Museum. Based on The Immortal Life of Henrietta Lacks, this book discussion will reach constituencies from a variety of St. Louis neighborhoods. A panel, consisting of a History professor of African American Studies, a clinical trial analyst, and a physician/medical ethicist, will lead the discussion.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-62. doi:10.1158/1538-7445.AM2011-LB-62
Abstract LB-66: Benefits and Barriers to Clinical Engagement with Cancer Consumer Representatives in New Zealand
Authors: Fletcher Stephanie 
Published: July 2012

Abstract
The Central Cancer Network (CCN), established in 2007, is one of four regional cancer networks in New Zealand. These networks were developed to facilitate initiatives contained in the Cancer Control Strategy Action Plan 2005–2010. The Network serves an urban and rural mixed population of approximately one million people.
The purpose of the Network is to take a proactive leadership, facilitation, collaborative and coordinated approach across organizational and service boundaries to ensure all providers of cancer prevention and care in the network area work together with the community to: manage the implementation of the Strategy and Action Plan in order to reduce the incidence and impact of cancer and the inequalities with respect to cancer, as well as to improve the journey of cancer patients and their family/wh ānau through the complex pathway of care, ensuring equitable, high quality, patient centered, evidence-based and multidisciplinary care.
There is an immense amount of research looking at the involvement of consumers in decision-making advisory and working groups. In New Zealand, there are consumer groups successfully working with clinicians in mental health and diabetes service improvement. However, there is limited research into the clinician's role and their influence of the functioning of such groups. Sitzia, Cotterell and Richardson (2006) spoke of the challenge of managing change when both professionals and lay people are involved in determining service change. Their work found that if professionals did not hold a belief that patient involvement would lead to positive service engagement, then the motivation to engage would be lost.
CCN proposes a two phased approach to improving clinical involvement with consumer representatives in cancer service improvement working groups:
1. Training workshops to disseminate the Health Service Co-Design Guide and Toolkit in 2011: The introduction of the Health Service Co-design Toolkit and Guide introduces the tools available to service providers to ensure that they fully utilize consumer experiences to enact service improvement.
2. Research proposal to conduct a qualitative research study in 2012, examining the barriers and benefits clinicians preserve enhance or hinder consumer participation in cancer service improvement groups. The research study will identify perceived barriers and benefits to clinicians engaging with consumer representatives and therefore work towards addressing the issues involved.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-66. doi:10.1158/1538-7445.AM2011-LB-66
Abstract LB-79: The Impact of Biospecimen Quality on Cancer Research and Patient Care
Authors: Newman-McCown Kimberly 
Published: July 2012

Abstract
The National Disease Research Interchange (NDRI) is a non-profit organization funded by The National Institute of Health. The organization was founded in 1980 at the request of researchers studying diabetes who found that obtaining the human pancreas they needed for their studies presented a major challenge to scientific development. NDRI was awarded a $3.6 million grant to participate in a two-year pilot study for the Genotype Tissue Expression (GTEx) initiative, which will afford all researchers an opportunity to have collaborative access to quality human tissue in order to advance cancer research and other disease discoveries.
The availability of high-quality biospecimens is essential to ongoing cancer research. These resources allow researchers to ask questions that can be answered only by testing hundreds or thousands of patient samples. Such an analysis would provide greater insight into how the cancer progresses and uncover potential new targets for interventions to disrupt the malignancy process. High-quality biospecimens are also essential for research aimed at the development of personalized medicine in which treatments and other interventions will be tailored to patients based on their genetic profile and the unique molecular features of their disease. However, the research that will lead to personalized cancer medicine is hampered at present by an inadequate supply of biospecimens that have been collected and stored according to standard protocols.
If an ample supply of high quality biospecimens were made available the following advances may be possible: the identification of specific proteins or other biomarkers associated with various stages or different types of individual cancers which could lead to new screening or diagnostic tests; the grouping of patients, based on biomarkers of the disease and other genetic characteristics to receive the best, most effective and least toxic treatment; and the identification of drug delivery or other agents to cancer cells and to measure responses to treatment. The necessary supply of biospecimens will be available for research only if patients agree to donate tissue when they undergo biopsy, surgery or other medical procedures. There are several ways in which patients, their families and the general public can help support cancer research that uses biospecimens: stay informed, consider donating a biospecimen, and spread the word.
Contact the National Disease Research Interchange (NDRI) 1–800–222–6374 or at http://www.ndriresource.org or visit our booth in the Exhibit Hall[[Unsupported Character –  ]]
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-79. doi:10.1158/1538-7445.AM2011-LB-79
Abstract LB-8: A novel function of Vps34 in regulation of cell proliferation
Authors: Su Hang , Henry Kevin Mc , Xu Teng , Yuan Zhi-Min 
Published: July 2012

Abstract
Many new insights into the biology of class III PI3Kinase have recently been reported. Most of these studies, however, used mainly transformed cells. It is unclear whether class III PI3Kinase works similarly in non-transformed mammalian cells. We explored this by depleting two non-transformed human epithelial cell lines of Vps34, the catalytic subunit of the lipid kinase using shRNA. Interestingly, in a stark contrast to transformed cells where depletion of Vps34 was associated with decreased growth, Vps34 deficiency in non-transformed cells resulted in a marked increase in cell proliferation. The deregulated autophagy function and E-cadherin-dependent cell-cell contacts found in Vps34-depleted cells appeared to be not involved in cell growth regulation as neither silence of Atg7 expression nor inactivation of E-cadherin had any effect on cell proliferation. Reporter luciferase-based ten-pathway screens suggested an altered activity of the MAPK pathway. Indeed, biochemical analysis indicated a sustained ERK activation resulting from the impediment of endosome-mediated EGFR turnover in Vps34 deficient cells. A contribution of the endosomal pathway to Vps34-mediated regulation of cell proliferation was further confirmed by using Rab5 and Rab11 mutants that perturbed early and recycling endosomes, respectively. Importantly, inactivation of Vps34 compromised the cellular barrier against oncogene-mediated transformation, as demonstrated by the increased susceptibility of Vps34 depleted cells to Ras-induced colony formation in vitro and tumor development in mice. Our data collectively uncover a novel role for the class III PI3Kinase-endosomal pathway in regulation of cell proliferation.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-8. doi:10.1158/1538-7445.AM2011-LB-8
Abstract LB-81: SHARE'S Achievements
Authors: Polinsky Deborah 
Published: July 2012

Abstract
SHARE's mission is to create and sustain a supportive community of women affected by breast or ovarian cancer in which survivors provide their experiences to newly-diagnosed women, their families and their friends. SHARE enables participants with the opportunity to receive and exchange information, support, strength, and hope. The organization's work focuses on patient empowerment, personal and community education, and public policy advocacy to bring about an improved quality of life, better heath care, and a cure for these diseases. For nearly thirty-five years SHARE has been providing peer support services and the latest research findings. SHARE is now an international organization which annually helps over 20,000 women and men affected by breast or ovarian cancer. It has helped establish similar affiliate programs around the United States and in Russia, the Ukraine, Bosnia, Poland and Israel.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-81. doi:10.1158/1538-7445.AM2011-LB-81